Epiq Capital Group, Llc Acquires 8,600 Shares of Cortexyme, Inc. (NASDAQ:CRTX) Stock

Cortexyme, Inc. (NASDAQ:CRTX) insider Epiq Capital Group, Llc bought 8,600 shares of Cortexyme stock in a transaction on Friday, May 10th. The stock was acquired at an average cost of $26.98 per share, for a total transaction of $232,028.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.

Epiq Capital Group, Llc also recently made the following trade(s):

  • On Wednesday, August 21st, Epiq Capital Group, Llc bought 4,965 shares of Cortexyme stock. The stock was acquired at an average cost of $25.35 per share, for a total transaction of $125,862.75.
  • On Monday, August 19th, Epiq Capital Group, Llc bought 2,800 shares of Cortexyme stock. The stock was acquired at an average cost of $26.46 per share, for a total transaction of $74,088.00.

NASDAQ CRTX opened at $24.95 on Thursday. Cortexyme, Inc. has a twelve month low of $19.50 and a twelve month high of $47.50. The firm’s fifty day moving average price is $35.10.

A number of equities research analysts have weighed in on CRTX shares. Zacks Investment Research raised Cortexyme from a “hold” rating to a “buy” rating and set a $33.00 target price on the stock in a report on Wednesday, August 14th. Credit Suisse Group started coverage on Cortexyme in a report on Monday, June 3rd. They set an “underperform” rating and a $14.00 price objective on the stock. Canaccord Genuity started coverage on Cortexyme in a report on Monday, June 3rd. They set a “buy” rating and a $42.00 price objective on the stock. Bank of America started coverage on Cortexyme in a report on Monday, June 3rd. They set a “neutral” rating and a $28.00 price objective on the stock. Finally, JMP Securities started coverage on Cortexyme in a report on Monday, June 3rd. They set a “mkt outperform” rating and a $53.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $34.00.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. acquired a new stake in shares of Cortexyme during the 2nd quarter valued at $78,000. Wells Fargo & Company MN acquired a new stake in shares of Cortexyme during the 2nd quarter valued at $191,000. Bank of New York Mellon Corp acquired a new stake in shares of Cortexyme during the 2nd quarter valued at $349,000. Landscape Capital Management L.L.C. acquired a new position in Cortexyme during the 2nd quarter worth about $535,000. Finally, Northern Trust Corp acquired a new position in Cortexyme during the 2nd quarter worth about $991,000. 1.17% of the stock is currently owned by institutional investors.

Cortexyme Company Profile

Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease.

See Also: How do analysts define an oversold condition?

Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.